Plaque Psoriasis

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

Test your knowledge below on pooled data from the ADORING trial program and stay up to date with clinical advancements in atopic dermatitis.

The interchangeable designation was granted to CT-P17, a biosimilar to adalimumab (Humira), for inflammatory diseases such as psoriasis.

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

This research highlights the potential of a tripeptide as a topical emollient-based cream for patients with psoriasis.

These findings were the result of a new analysis of the inflammatory characteristics associated with the efficacy sustenance of biologic medications for psoriasis.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

These data on patients in Japan demonstrate positive efficacy and safety findings in real-world settings, with uniquely positive results among bio-naïve patients.

In this analysis, links between psoriasis and metabolic and cardiovascular risk were evaluated along with correlations between biomarkers and severity.

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.